2020
Cannabinoids
De Aquino J, Arnaout B. Cannabinoids. 2020, 153-167. DOI: 10.1007/978-3-030-33404-8_10.Peer-Reviewed Original ResearchCannabis use disorderUse of cannabinoidsPotential pharmacokinetic interactionsEffects of cannabinoidsDose-dependent effectPharmacokinetic interactionsPsychotropic medicationsRisk factorsPsychosocial treatmentsPsychiatric disordersUse disordersAddiction specialistsHealthcare providersPsychomotor functioningCannabinoidsSynthetic cannabinoidsDisordersMedicinal useMedicationsPatientsProgressionBrief Training on Medication-Assisted Treatment Improves Community Mental Health Clinicians’ Confidence and Readiness to Address Substance Use Disorders
Iheanacho T, Bommersbach T, Fuehrlein B, Arnaout B, Dike C. Brief Training on Medication-Assisted Treatment Improves Community Mental Health Clinicians’ Confidence and Readiness to Address Substance Use Disorders. Community Mental Health Journal 2020, 56: 1429-1435. PMID: 32062717, PMCID: PMC7429311, DOI: 10.1007/s10597-020-00586-8.Peer-Reviewed Original ResearchConceptsSubstance use disordersMedication-assisted treatmentCommunity mental health cliniciansMental health cliniciansHealth cliniciansPost-training questionnairesUse disordersDisease modelsRoutine practiceCliniciansFactor 1Factor 2Brief trainingDisordersSignificant changesQuestionnaireLimited awarenessTreatmentPublic sector settingsAddictionPreMedicationsPatientsLow confidenceDisease
2010
Sedative-Hypnotics and Anxiolytics
Arnaout B, Petrakis I. Sedative-Hypnotics and Anxiolytics. 2010, 511-523. DOI: 10.1007/978-1-4419-0338-9_23.Peer-Reviewed Original ResearchCentral nervous system depressantsPsychiatric adverse eventsGroup of medicationsNon-benzodiazepine hypnoticsNon-medical useAdverse eventsSexual dysfunctionSleep disordersSedative hypnoticsPsychotic manifestationsCognitive disordersTherapeutic valueGeneral medicineAnxiety disordersMedicationsDisordersAnxiolyticsDeleterious effectsAbuseHypnoticsDysfunctionBenzodiazepinesEpidemiologyIntoxicationNeurology
2007
Aripiprazole as an adjunctive treatment for refractory unipolar depression
Hellerstein DJ, Batchelder S, Hyler S, Arnaout B, Corpuz V, Coram L, Weiss G. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2007, 32: 744-750. PMID: 18164528, DOI: 10.1016/j.pnpbp.2007.11.024.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsAripiprazoleBrief Psychiatric Rating ScaleDepressive DisorderDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleDrug EvaluationFemaleHumansMaleMiddle AgedPiperazinesProspective StudiesQuinolonesSocial BehaviorTime FactorsTreatment OutcomeConceptsHDRS-24Adjunctive treatmentSNRI medicationsUnipolar depressionCurrent episodeWeek open label studyTreatment-resistant major depressionCurrent DSM-IV diagnosisEffectiveness of aripiprazoleRefractory unipolar depressionOpen-label studyEffective adjunctive treatmentDSM-IV diagnosisFluoxetine equivalentsSNRI treatmentWeek 12Baseline severityMean doseMajor depressionTreatment respondersSide effectsSSRIsMaximum doseAripiprazoleMedications